Matrix metalloproteinases (MMPs) have been implicated in progression and metastases of different tumours. The balance between the MMPs and their natural inhibitors (tissue inhibitors of matrix metalloproteinases; TIMP) seems to be an important factor related to this role. Here, the expression of MMP-2 and -9 along with TIMP-1 and -2 was examined in prostate cancer tissue. A total of 40 radical prostatectomy specimens were embedded in paraffin and immunohistochemical staining was performed to detect MMP-2 and -9, and TIMP-1 and -2. The immunoreactivity was assessed semiquantitively using routine light microscopy. The intensity of staining was correlated to preoperative PSA, T category, Gleason score and clinical parameters of the specimens. The imbalance of MMPs and TIMPs was recognised as a significant loss of TIMP-1 in malignant epithelium and an upregulation of MMPs. Palpable tumours (T2, T3) expressed significantly more MMP-2 and significantly less MMP-9 than T1c tumours. Our data are in accordance with other literature reports in that an imbalance of MMPs and TIMPs is found in malignant tumours. The observed imbalance of MMP and TIMP is mainly caused by a loss of TIMP-1. Furthermore, palpable tumours demonstrated significantly more MMP-2 and significantly less MMP-9 expression than nonpalpable tumours.
Introduction
Throughout the last decades, the interaction between malignant cells and extracellular matrix (ECM) has been the object of intensive studies, with particular focus on the biochemical degradation of the basement membrane (BM). The main structural components of the BM are collagen type IV, V, laminin, entacin, fibronectin and proteoglycans. The ratio of these components and the presence or absence of fibronectin define the type of BMs found in the different tissues. Collagen type IV is found exclusively and is present in all BMs. 1 Matrix metalloproteinases (MMPs) are a family of highly homologous Zn 2+ -dependent enzymes, capable of degrading the ECM and BM. They are present in healthy individuals and have been shown to play an important role in physiological processes such as wound healing, 2 bone resorption 3 and pregnancy. 4 However, the main interest in MMPs relates to their role in certain pathological mechanisms where the breakdown of the ECM is a key feature. 5 Such mechanisms include rheumatoid arthritis, 3, 6 liver fibrosis 7 and cancer, where degradation of the BM and ECM is the first step in invasion and metastases.
The continuously growing MMP gene family contains 17 members at present. The MMPs have been subdivided into four groups, which are defined by the substratespecific degradation of the ECM and BM, namely, the collagenases, stromelysins, gelatinases and matrilysin. The more recently discovered membrane-type MMPs (MT-MMPs) probably represent a new subgroup. 8 The proteinases MMP-2 (synonym: gelatinase A; 72 kDa) and MMP-9 (gelatinase B; 92 kDa) belong to the group of the gelatinases. The substrates of MMP-2 and MMP-9 are primarily collagen IV, V, elastin, gelatin, fibronectin and laminin. 9 MMP-2 and MMP-9 are well known as promoters for cancer invasion and metastases in a variety of different tumours: colon, 10 breast, 11 brain tumours 12 and many others. Also the expression of MMP-9 and MMP-2 in benign and malignant prostate tissue is documented. 13, 14 Correlation between MMP expression and clinical parameters is rare. The activity of MMPs is regulated by gene transcription, 15 activation of the proenzymes 16 and inhibition of the activated proteinases by different inhibitors. The most important natural inhibitors of these proteinases are the tissue inhibitors of matrix metalloproteinases (TIMP). So far, four TIMPs (À1, À2, À3 and À4) are known. MMP-2 is predominantly inhibited by TIMP-2 17 and TIMP-4, 18 while MMP-9 is inhibited mainly by TIMP-1. 19 An imbalance between MMPs and TIMPs expression was shown in recent studies to be connected with a variety of different tumours, for example, lung, 20 colon, 21 breast 22 and prostate. 23 In the present study, the expression of MMP-2 and -9, and TIMP-1 and -2 in prostate cancer tissue was examined using immunohistochemical methods. The findings were correlated to clinical parameters.
Material and methods
Surgical specimens after radical prostatectomy were obtained from 40 patients. The average age of the patients was 63.7 y (52-74 y). The mean PSA was 9.7 mg/l (1.7-8.2 mg/l). Four patients had microscopic lymph node metastasis. None of the patients had had previous antiandrogen therapy. On digital rectal examination (DRE), performed by the author/coauthor, 20 carcinomas were classified as T2-3, and 20 were impalpable (T1c). In all cases, an adenocarcinoma of the prostate was present. pT2 and pT3 tumours were found in 27 and 13 patients, respectively. In nine cases, the seminal vesicles were invaded and 12 had a positive surgical margin. Six patients had a Gleason score of p3, 30 patients had a Gleason score of between 4 and 6, and four patients had a Gleason score of X7 ( Table 1) . As a control group, we used a representative prostates section without cancer from 20 patients who underwent cystoprostatectomy because of bladder cancer.
Prostatectomy specimens were inked and fixed in 4% paraformaldehyde phosphate-buffer saline, pH 7.0 at room temperature, processed according to Schmid and McNeal 24 and embedded in paraffin. The 4 mm tissue sections were deparaffinised and used for immunohistochemical staining as described by Boag and Young. 23 The concentrations of primary antibodies were 4 mg/ml for MMP-2 (Calbiochem s , Cambridge, MA, USA), 8 mg/ ml for MMP-9 (Calbiochem s , Cambridge, MA, USA), 7.5 mg/ml for TIMP-1 (ICN s , Aurora, Ohio, USA) and 15 mg/ml for TIMP-2 (ICN s , Aurora, Ohio, USA). The immunoreactivity of an index carcinoma lesion in all sections was assessed using routine light microscopy. We utilised the degree (0-3) of staining in stroma, benign and tumour cells separately. The intensity of staining was correlated to DRE, PSA level, tumour category and Gleason score. In each staining, positive and negative controls were always performed. The numeric outcome of the staining was biometrically analysed by using the Mann-Whitney U-test and the Kruskal-Wallis test.
Results
The average staining degree of tumour, stroma and normal epithelium is listed in Table 2 and Figure 1 . An initial background staining was identified and removed by using standard negative controls. All metalloproteinases as well as their inhibitors appeared as a cytoplasmic staining. The tumour cells showed a weak to moderate immunoreactivity for MMP-2. In the stroma cells surrounding the malignant epithelium, significantly stronger (P ¼ 0.0001) immuno reactivity was identified compared to stroma cells surrounding normal epithelium. The stromal staining was clearly due to staining cytoplasm. The ECM, especially the collagen fibres, were found to be negative (Figure 2 ). The staining in tumour and normal epithelial cells showed no significant difference (Table 2) .
Tumour and stroma cells stained moderately to strongly for MMP-9, but the normal epithelium showed only weak staining. In addition, stroma cells surrounding the tumour demonstrated a significantly stronger (P ¼ 0.01) MMP-9 immunoreactivity compared to stroma surrounding the normal epithelium ( Figure 3) . The difference in staining between tumour and benign epithelial cells was not significant.
The normal epithelium was strongly stained for TIMP-1 (Figure 4) , whereas in the tumour epithelium no or only very weak staining was present ( Table 2 ). The different immunoreactivity was highly significant (Po0.001). Furthermore, the stroma cells in whole of the prostate were significantly more stained than the tumour epithelium (P ¼ 0.002) ( Figure 5 ).
For TIMP-2, the tumour epithelium showed no significant difference compared to the benign epithelium. The stroma was significantly less (P ¼ 0.005) stained than the tumour cells ( Figure 6 ). The stroma cells surrounding the tumour were significantly less (P ¼ 0.001) stained compared to the stroma cells that surround the normal epithelium.
For MMP-2 and -9, the Kruskal-Wallis test showed no significant difference in staining correlated to Gleason MMP-2 and -9 in prostate cancer tissue B Brehmer et al score. These was only a trend for increasing amounts of MMP-2 (P ¼ 0.06) and MMP-9 (P ¼ 0.076) if correlated to increasing Gleason score. pT category and PSA level did not show any correlation to immunoreactivity. Concerning the DRE, the immunoreactivity of MMP-2 in stroma (P ¼ 0.005) and tumour cells (P ¼ 0.009) was significantly stronger in palpable cancers. T1c tumours had significantly stronger staining for MMP-9 in tumour (P ¼ 0.005) and stroma cells (P ¼ 0.001) compared to palpable tumours. We could not demonstrate any significant difference for TIMP-1 and -2 in palpable and nonpalpable tumours (Table 3 ).
Discussion
Our understanding of the role of MMPs and TIMPs in tumour invasion and metastases has changed over the last few years. We now know that: (1) the balance between MMPs and their inhibitors allows control over proteolytic degradation of the matrix, invasion and cell MMP-2 and -9 in prostate cancer tissue B Brehmer et al growth; and (2) that an imbalance of MMPs and TIMPs is an important contributing factor in tumour progression. Davies et al 25 measured the level of MMP-2 and -9 by zymography in bladder cancer tissue. The mean levels of MMP-9 were significantly higher in tumour compared with normal samples. Levels of inactive proforms of MMP-2 did not differ between normal and malignant urothelium, but the activated MMP-2 levels were higher in malignant tissues. 25 An increased level of MMPs could be demonstrated in colorectal cancer, 21, 26 in breast cancer, 22 skin cancers like melanoma 27 and many others.
The discussion on the function of TIMPs remains controversial. Some authors could reduce the invasive and metastatic potential of tumour cells by increasing the TIMP level in cell culture experiments. Stearns et al In contrast, recent studies showed a dose-dependent effect for tumour cell invasion for TIMP-2. A stimulatory effect of TIMP-2 for invasion was observed in lower concentrations and an inhibiting effect in higher concentrations. 32 TIMP-2 is a bifunctional enzyme; it is an inhibitor of MMPs but also participates in activation of pro-MMPs. The secreted pro-MMP forms a complex with a TIMP-2 molecule. Special membrane type MMPs (MT-MMP) cleave this complex into the active form of MMP. 33 This immunohistochemical study showed the expression of TIMP-2 to be slightly increased in tumour cells compared to nonmalignant tissue. This finding supports the relevance of TIMP-2 in the activation of the MMPs.
The location of the principal source of MMPs and TIMPs has been investigated in previous studies. Gallegos et al 21 described immunohistochemical staining of MMP-2 and -9 in colorectal cancers in surrounding stroma cells which is consistent to our findings. Poulsom et al undertook in situ hybridisation studies to detect MMP-2 and TIMP-2 in 12 colorectal carcinomas. The neoplastic cells showed sparse labelling for MMP-2, compared with the labelling seen in the surrounding stroma. 26 Similarly, we found that the most intensive expression of MMP-2 and -9 was present in stroma cells surrounding the malignant epithelium. As yet the mechanism(s) whereby the cancer cells influence the production of the MMPs in the stroma cells is unknown.
Our results for prostate tissue were in accordance with and therefore confirm previous investigations in other cancers: that is to say, MMP-2 and -9 are present in increased amounts in malignant tissue, whereas TIMP-1 is scarcely detected. We found an almost complete absence of TIMP-1 in malignant prostatic epithelium. Only TIMP-2 was present in a slightly increased amount compared to nonmalignant tissue. Identical expression patterns were described in the epithelial tumors of the ovary by Sakata et al. 34 The first indication that nonpalpable prostate cancers are of lower grade and smaller than palpable tumours was published by Cooner et al 35 Geary and Stamey 36 demonstrated in 270 patients with locally confined prostate carcinomas that nonpalpable tumours had a more favourable pathology compared to palpable disease. Epstein et al 37 reported that 15% of T1c cancers already showed a focal capsular penetration and in 34% established capsular penetration was present. We all know the interobserver variation factor of DRE. In this study, the DRE was performed by two urologists and only if examination was unanimous the patient was included. Here, we demonstrated significantly increased expression of MMP-2 for palpable tumours (T2-3) compared with nonpalpable tumours (T1c), and that the nonpalpable tumours expressed significantly more MMP-9.
Both MMP-2 and -9 enzymes digest nearly identical substrates, namely gelatins, collagen IV and V, elastin and proteoglycans. 9 In addition, MMP-2 can digest fibronectin, lamenin, and collagen VII and XI. Agren et al 38 examined MMP-2 and -9 in wound fluid and their association with deposition of collagen during wound MMP-2 and -9 in prostate cancer tissue B Brehmer et al repair. He found inversely correlated MMP-9 levels to deposited collagen, and concluded that the level of MMP-9 in the early inflammatory phase can predict the amount of collagen deposited in the wound healing process. 38 Conversely, the MMP-2 level in wound fluid had no effect on the amount of collagen that was deposited.
Conclusions
Therefore, the dysregulation of MMPs and TIMPs is essentially caused by a significant loss of TIMP-1 and a increased secretion of MMP-2 and -9. The location of enzymatic activity seems to be in the stroma cells surrounding the tumour cells. The correlation of MMPs and Gleason score is probable; however, the number of specimens was too small to obtain a significant result.
We observed increased amounts of MMP-9 in nonpalpable tumours (T1c). Assessment of the stroma collagen in the prostate cancers was not performed. However, an increased amount of MMP-9 along with an increased dissimilation of stroma collagen could provide an explanation for the absence of the characteristic induration found in T1c tumours on rectal examination.
